Proactive Investors - Run By Investors For Investors

OptiBiotix Health inks distribution deal covering Greece and Cyprus

The unnamed local partner for CholBiome was chosen for its distribution network
cholesterol test
The company has developed CholBiome to combat cholesterol and high blood pressure

OptiBiotix Health plc (LON:OPTI) shares rose on Thursday following news the firm has signed a distribution agreement for its cholesterol and blood pressure reducing LPLDL bacteria strain in Greece and Cyprus.

The unnamed local partner for CholBiome was chosen for its customer network, which also covers the Middle East and its track record of promoting and developing products. It also has access to a number of international clinics.

READ: OptiBiotix inks agreement to manufacture LPLDL in US market

Optibiotix has granted an exclusive three-year deal, which is subject to hitting certain sales targets, in return for local product registrations. No financial details were mentioned.

In September, the company inked a distribution contract for Bulgaria, while CholBiome is now on sale in the UK online.

“This agreement is a strategic step to build the distribution sales channel for CholBiome products in the European market and eliminates intermediates in the supply chain with a shorter route to market and higher value to OptiBiotix,” said OptiBiotix commercial director Per Rehné.

“The company has already placed an initial order to be used for pre-marketing activities and we expect further orders to support a consumer launch in the first-quarter of 2019."

In early morning trading, OptiBiotix shares were up 0.8% at 66.50p.

 -- Adds share price --

View full OPTI profile View Profile

OptiBiotix Health plc Timeline

Related Articles

myLotus testing kit
October 31 2018
The launch at the Fertility Show in London at the start of November is the first step in a switch in focus brought about by new executive chairman Matthew Walls
Nemaura Medical Inc CEO Dr Faz Chowdhury
November 05 2018
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018
Proton Therapy sign
October 10 2018
The broker says the cancer treatment developer could potentially take the entire share of the growth market from ageing cyclotron companies

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use